E. Thunnissen Et Al. , "Crizotinib-Treated ALK Immunopositive Metastasized NSCLC is Associated with an Unfavorable Prognosis when FISH Negative," JOURNAL OF THORACIC ONCOLOGY , vol.13, no.10, 2018
Thunnissen, E. Et Al. 2018. Crizotinib-Treated ALK Immunopositive Metastasized NSCLC is Associated with an Unfavorable Prognosis when FISH Negative. JOURNAL OF THORACIC ONCOLOGY , vol.13, no.10 .
Thunnissen, E., Lissenberg-Witte, B., Van den Heuvel, M., Monkhorst, K., Skov, B., Sorensen, J., ... Mellemgaard, A.(2018). Crizotinib-Treated ALK Immunopositive Metastasized NSCLC is Associated with an Unfavorable Prognosis when FISH Negative. JOURNAL OF THORACIC ONCOLOGY , vol.13, no.10.
Thunnissen, E. Et Al. "Crizotinib-Treated ALK Immunopositive Metastasized NSCLC is Associated with an Unfavorable Prognosis when FISH Negative," JOURNAL OF THORACIC ONCOLOGY , vol.13, no.10, 2018
Thunnissen, E. Et Al. "Crizotinib-Treated ALK Immunopositive Metastasized NSCLC is Associated with an Unfavorable Prognosis when FISH Negative." JOURNAL OF THORACIC ONCOLOGY , vol.13, no.10, 2018
Thunnissen, E. Et Al. (2018) . "Crizotinib-Treated ALK Immunopositive Metastasized NSCLC is Associated with an Unfavorable Prognosis when FISH Negative." JOURNAL OF THORACIC ONCOLOGY , vol.13, no.10.
@article{article, author={E. Thunnissen Et Al. }, title={Crizotinib-Treated ALK Immunopositive Metastasized NSCLC is Associated with an Unfavorable Prognosis when FISH Negative}, journal={JOURNAL OF THORACIC ONCOLOGY}, year=2018}